We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
No comments yet, be the first to start the discussion!
4 - pembrolizumab
In prostate cancer, CDK12 mutations occur in 5%−7% of patients with mCRPC, and most are biallelic inactivations.
CDK12-altered/mutated prostate cancer is an aggressive subtype with poor responses and outcomes to hormonal, taxane, and PARP inhibitor therapies. A proportion of these patients may respond favorably to PD-1 inhibitors, which implicates CDK12 deficiency in immunotherapy sensitivity.
He should be treated with cabazitaxel and pembrolizumab. CDK12 does not respond to PARP inhibitors.
He should be treared with pembrolizumab
pembrolizumab as explained by Gregory Lewis
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.